Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoviz Technologies Ltd.INVZ · Entity 6753 | Chief R&D Officer | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoviz Technologies Ltd.
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 397,001 |
Reported balance
After 2026-08-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 66,336 · Balance 397,001 F1: Represents 66,336 Restricted Share Units (RSUs) granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable. F2: Includes 213,724 ordinary shares issuable upon vesting of RSUs; of which (a) 2,005 RSUs granted August 9, 2022, vesting quarterly through 2026; (b) 8,540 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 12,471 RSUs granted February 27, 2024, with 2,013 vesting quarterly through 2027 and 10,458 vesting quarterly through 2028; (d) 25,452 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 13,684 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 37,188 RSUs granted August 5, 2025, vesting quarterly through 2029; (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029; and (h) 66,336 RSUs granted August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030. F3: Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2033-08-04 | Direct | 71,072 |
Reported balance
After 2026-08-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-04 · Grant · Acquired 71,072 · Balance 71,072 F4: Share options granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 66,336 Restricted Share Units (RSUs) granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable.
F2: Includes 213,724 ordinary shares issuable upon vesting of RSUs; of which (a) 2,005 RSUs granted August 9, 2022, vesting quarterly through 2026; (b) 8,540 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 12,471 RSUs granted February 27, 2024, with 2,013 vesting quarterly through 2027 and 10,458 vesting quarterly through 2028; (d) 25,452 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 13,684 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 37,188 RSUs granted August 5, 2025, vesting quarterly through 2029; (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029; and (h) 66,336 RSUs granted August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030.
F3: Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share.
F4: Share options granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 5, 2026 20:13 UTC | Innoviz Technologies Ltd. INVZ · Entity 6753 | GrantShare Option · Derivative | 71,072 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001178913-26-003863 · ownership.xml · derivative · entry 2 Moscovici Avishay Ben · CIK 0002030150 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,072 Underlying: Ordinary Shares · 71,072 shares Expires 2033-08-04 F4 · derivative.exercise_date: Share options granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Read SEC document |
| August 04, 2026 Filed Aug 5, 2026 20:13 UTC | Innoviz Technologies Ltd. INVZ · Entity 6753 | GrantOrdinary Shares | 66,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003863 · ownership.xml · nonDerivative · entry 1 Moscovici Avishay Ben · CIK 0002030150 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,001 F1 · shares: Represents 66,336 Restricted Share Units (RSUs) granted on August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable. F2 · balance_after: Includes 213,724 ordinary shares issuable upon vesting of RSUs; of which (a) 2,005 RSUs granted August 9, 2022, vesting quarterly through 2026; (b) 8,540 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 12,471 RSUs granted February 27, 2024, with 2,013 vesting quarterly through 2027 and 10,458 vesting quarterly through 2028; (d) 25,452 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 13,684 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 37,188 RSUs granted August 5, 2025, vesting quarterly through 2029; (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029; and (h) 66,336 RSUs granted August 4, 2026, one-fourth vesting on August 4, 2027, remainder vesting quarterly through 2030. F3 · balance_after: Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.